Interleukin-10 Prevents Diet-Induced Insulin Resistance by Attenuating Macrophage and Cytokine Response in Skeletal Muscle by Hong, Eun-Gyoung et al.
Interleukin-10 Prevents Diet-Induced Insulin Resistance
by Attenuating Macrophage and Cytokine Response in
Skeletal Muscle
Eun-Gyoung Hong,
1,2 Hwi Jin Ko,
1,3 You-Ree Cho,
2 Hyo-Jeong Kim,
2 Zhexi Ma,
1 Tim Y. Yu,
2
Randall H. Friedline,
3 Evelyn Kurt-Jones,
4 Robert Finberg,
4 Matthew A. Fischer,
5
Erica L. Granger,
5 Christopher C. Norbury,
5 Stephen D. Hauschka,
6 William M. Philbrick,
2
Chun-Geun Lee,
7 Jack A. Elias,
7 and Jason K. Kim
1,2,3,4
OBJECTIVE—Insulin resistance is a major characteristic of
type 2 diabetes and is causally associated with obesity. Inﬂam-
mation plays an important role in obesity-associated insulin
resistance, but the underlying mechanism remains unclear. Inter-
leukin (IL)-10 is an anti-inﬂammatory cytokine with lower circu-
lating levels in obese subjects, and acute treatment with IL-10
prevents lipid-induced insulin resistance. We examined the role
of IL-10 in glucose homeostasis using transgenic mice with
muscle-speciﬁc overexpression of IL-10 (MCK-IL10).
RESEARCH DESIGN AND METHODS—MCK-IL10 and wild-
type mice were fed a high-fat diet (HFD) for 3 weeks, and insulin
sensitivity was determined using hyperinsulinemic-euglycemic
clamps in conscious mice. Biochemical and molecular analyses
were performed in muscle to assess glucose metabolism, insulin
signaling, and inﬂammatory responses.
RESULTS—MCK-IL10 mice developed with no obvious anomaly
and showed increased whole-body insulin sensitivity. After 3
weeks of HFD, MCK-IL10 mice developed comparable obesity to
wild-type littermates but remained insulin sensitive in skeletal
muscle. This was mostly due to signiﬁcant increases in glucose
metabolism, insulin receptor substrate-1, and Akt activity in
muscle. HFD increased macrophage-speciﬁc CD68 and F4/80
levels in wild-type muscle that was associated with marked
increases in tumor necrosis factor-, IL-6, and C-C motif chemo-
kine receptor-2 levels. In contrast, MCK-IL10 mice were pro-
tected from diet-induced inﬂammatory response in muscle.
CONCLUSIONS—These results demonstrate that IL-10 in-
creases insulin sensitivity and protects skeletal muscle from
obesity-associated macrophage inﬁltration, increases in inﬂam-
matory cytokines, and their deleterious effects on insulin signal-
ing and glucose metabolism. Our ﬁndings provide novel insights
into the role of anti-inﬂammatory cytokine in the treatment of
type 2 diabetes. Diabetes 58:2525–2535, 2009
T
ype 2 diabetes is the most common metabolic
disease in the world, affecting 250 million
people, and is characterized by insulin resis-
tance, dyslipidemia, and hyperglycemia (1–3).
Skeletal muscle insulin resistance is a major characteristic
of numerous metabolic disorders including diabetes, obe-
sity, and HIV-associated lipodystrophy, and plays a pri-
mary role in the development of type 2 diabetes (4).
Although the causal relationship between obesity and
insulin resistance is widely accepted, the underlying mech-
anism remains complex and debatable (5). A concept
(Randle’s glucose–fatty acid cycle) introduced 40 years
ago, which has since been modiﬁed, proposes that hyper-
lipidemia and fatty acids cause insulin resistance by
downregulating insulin signaling and glucose metabolism
in skeletal muscle (6–8). More recently, a new concept
emerged stating that insulin resistance is associated with
chronic low-grade inﬂammation (9). In this regard, proin-
ﬂammatory cytokines, such as tumor necrosis factor
(TNF)- and interleukin (IL)-6, are elevated in obese,
diabetic subjects and are shown to cause insulin resis-
tance in humans and animals (10–12). In contrast, plasma
levels of anti-inﬂammatory cytokine, IL-10, are positively
related to insulin sensitivity in healthy subjects and are
reduced in obese and diabetic subjects (13–15).
IL-10 is a Th2-type cytokine that is produced by a wide
range of immunological cell types, including monocytes/
macrophages, and it is a potent inhibitor of the proinﬂam-
matory cytokines and chemokines (16). Immuno-
suppressive effects of IL-10 involve both inhibition of
cytokine synthesis (e.g., TNF-, IL-6) and their biological
activities on target cells (17). The intracellular signaling
event affected by IL-10 involves nuclear translocation of
the signal transducer and activator of transcription 3
(STAT3) and transcription of STAT3-responsive genes
including SOCS3 (18). Previous studies examining the role
of IL-10 in diabetes have been primarily directed toward
the pancreatic -cells and the pathogenesis of type 1
diabetes (19). IL-10 was shown to increase pancreatic
-cell functions in response to glucose in vitro, and IL-10
treatment signiﬁcantly reduced insulitis and prevented
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regard, our recent study (21) was the ﬁrst to report that
IL-10 affects peripheral glucose metabolism and that co-
treatment with IL-10 attenuates insulin resistance follow-
ing acute lipid infusion. This preliminary observation
suggests that IL-10 may be a positive regulator of insulin
sensitivity, a notion that is consistent with other reports
indicating that polymorphisms and haplotypes of the IL-10
promoter are associated with obesity and insulin resis-
tance (22). Interestingly, a recent report from Lumeng et
al. (23) demonstrated that adipose tissue macrophages
from lean animals express polarization toward an alterna-
tively activated state, and this was associated with in-
creased expression of IL-10. This study further showed
that IL-10 increases glucose uptake and protects against
TNF-–mediated insulin resistance in isolated adipocytes
(23). However, the metabolic role of IL-10 in skeletal
muscle, a major organ of glucose disposal, is unknown.
Thus, we have generated transgenic mice with muscle-
speciﬁc overexpression of IL-10 to investigate the role of
IL-10 in glucose homeostasis. In this article, we demon-
strate that IL-10–overexpressing mice are more insulin
sensitive and are protected from diet-induced muscle
insulin resistance partly due to IL-10–mediated attenua-
tion of the macrophage and cytokine response and to
increased insulin signaling in skeletal muscle.
RESEARCH DESIGN AND METHODS
Effects of IL-10 treatment on diet-induced obesity. Male C57BL/6 mice at
10 weeks of age were purchased from The Jackson Laboratory and housed
under controlled temperature and lighting with free access to food and water.
To determine the effects of a 3-day IL-10 treatment on diet-induced insulin
resistance, mice were fed a high-fat diet (HFD) (55% fat by calories; Harlan
Teklad TD93075, Madison, WI) (supplementary Table in the online appendix
[available at http://diabetes.diabetesjournals.org/cgi/content/full/db08-1261/
DC1]) or standard diet (Harlan Teklad LM-485) for 3 weeks, and IL-10 (2
g/day) or saline was administered using Alzet osmotic pumps during the last
3 days of the diet period (n  5–8). Hyperinsulinemic-euglycemic clamps
were performed in conscious mice at the end of feeding and IL-10
treatment. All procedures were approved by the institutional animal care
and use committee at the University of Massachusetts Medical School,
Pennsylvania State University College of Medicine, and Yale University
School of Medicine.
Generation of muscle creatine kinase IL-10 mice. In this transgenic
model, the expression of mouse IL-10 was restricted to skeletal muscle by
placing it under the control of a 1.3-kb segment of the mouse muscle creatine
kinase (MCK) promoter (1256MCK-3Emut) (24,25). To restrict the transgene
expression to skeletal muscle and avoid any potential consequences of
expression in cardiac muscle, we used a modiﬁed (3Emut) MCK promoter in
which the three conserved E boxes were mutated. To facilitate construction
of the transgene, we converted the most downstream in a series of BstEII sites
in this promoter into a HindIII site using a PCR-based site-directed mutagen-
esis method (Stratagene, La Jolla, CA), which then allowed excision of the
promoter from the plasmid of origin and subsequent insertion into a transgene
expression vector designed by the molecular core of Yale Diabetes and
Endocrinology Research Center. In this vector, sequences to be expressed
were ﬂanked downstream by a 2.2-kb segment of human growth hormone
(hGH) sequences. The addition of the hGH exons and introns provides
polyadenylation/termination signals and splice sites and has been shown to
increase transgene expression efﬁciency; these sequences are not translated.
A 550-bp cDNA for murine IL-10 (26) was then inserted immediately down-
stream of the promoter. The completed MCK(mut)-IL10-hGH transgene was
excised with XhoI/NotI to exclude vector sequences, gel isolated, and puriﬁed
using DEAE column elution and microdialysis.
Microinjection of SJL  C57BL/6 F2 oocytes with the puriﬁed transgene
construct was carried out by the Yale Transgenic Mouse Facility. Founders
were identiﬁed by PCR screening of tail biopsy lysates with primers speciﬁc
for a 171-bp segment in the growth hormone sequences at the 3	 end of the
transgene. Of 15 transgenic founder mice that were identiﬁed, 6 founders with
strong expression of the transgene were backcrossed to C57BL/6 mice to
generate MCK-IL10 mice and wild-type littermates on the C57 background.
IL-10 expression levels were then evaluated in the transgenic F1 mice
representing each of the founder lines by real-time quantitative PCR analysis
of muscle RNA with primers for the growth hormone tag and primers for
mouse glyceraldehyde 3-phosphate dehydrogenase serving as an internal
control for signal normalization. Following birth and weaning, the F1 mice
(MCK-IL10) showed no obvious anomalies, and they exhibited similar patterns
of growth compared with the wild-type littermate controls. Transgenic F1
mice were selected based on high and low levels of IL-10 expression in
skeletal muscle and were then backcrossed to C57BL/6 mice to generate the
F2 mice. All of the metabolic characterization was performed using F5 and F6
mice from the low expressor lines.
Body composition analysis and metabolic cages. Whole-body fat and lean
mass were noninvasively measured in conscious mice using
1H-MRS (Echo
Medical Systems, Houston, TX). A 3-day measurement of food intake, energy
expenditure, respiratory exchange ratio, and physical activity were performed
using the metabolic cages (TSE Systems, Bad Homburg, Germany).
Hyperinsulinemic-euglycemic clamps. Following an overnight fast (15 h),
a 2-h hyperinsulinemic (2.5 mU  kg
1  min
1 with 150 mU/kg body wt
priming)-euglycemic clamp was conducted in conscious mice with [3-
3H]glu-
cose and 2-deoxy-D-[1-
14C]glucose to assess glucose metabolism in individual
organs (21).
Molecular analysis for insulin signaling and inﬂammatory response in
skeletal muscle. Muscle samples were obtained at the end of clamps or at 15
min following insulin injection to measure in vivo insulin signaling activity
using anti–insulin receptor substrate (IRS)-1 (Millipore, Billerica, MA) and Akt
antibodies (Cell Signaling, Danvers, MA). For the following measurements,
tissue samples were obtained from MCK-IL10 mice at basal state. Tissue-
speciﬁc STAT3 protein expression and tyrosine phosphorylation were mea-
sured using STAT3 (p-Tyr705) antibody (Cell Signaling Technology, Beverly,
MA) as previously described (27). For muscle CD68, C-C motif chemokine
receptor (CCR)-2, phosphor–c-Jun NH2-terminal protein kinase (JNK) 1, and
JNK1 protein levels, muscle tissues (50 mg) were prepared and polyclonal
antibodies against CD68, CCR2, phospho-JNK1, and JNK1 (Santa Cruz Bio-
tech, Santa Cruz, CA) were used. Local and serum levels of IL-10, IL-6, and
TNF- were measured using Immunoassay kits (Alpco Diagnostics, Salem,
NH).
Immunoﬂuorescence study. Brieﬂy, muscle samples were taken from the
mouse, and their frozen sections were made. Tissue sections were ﬁxed in
acetone/methanol (1:3) for 10 min and washed with PBS plus Tween 20
(PBST) (10 mmol/l sodium phosphate, 150 mmol/l sodium chloride, 0.3%
Tween 20, pH 7.8) two times. Tissue sections were blocked in PBST
containing 5% goat serum for1ha troom temperature and washed with PBST
two times. Anti-F4/80 antibody (Abcam, Cambridge, MA) was used as a
speciﬁc antibody for macrophage, and anti-IgG ﬂuorescein isothiocyanate
(FITC) (Sigma-Aldrich, St. Louis, MO) was used as a secondary antibody.
Totals of 70, 80, and 100% ethanol were used for each 1 min for dehydration,
and tissue sections were dried by air. Nuclei were stained with 4	,6-diamidino-
2-phenylindole (VECTA Lab, Burlingame, CA), and ﬂuorescence was analyzed
using a ﬂuorescence microscope.
Mononuclear cell preparation. Quadriceps and gastrocnemius muscles
from both hindlimbs of anesthetized mice were quickly isolated, minced, and
transferred to a ﬂask containing Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 5% fetal bovine serum and 0.2% collagenase
(Sigma-Aldrich). Tissues were incubated for1ha t37°C with gentle shaking,
passed over a 70-m ﬁlter, washed, and run over a 70/40 Percoll gradient to
isolate mononuclear cells. Cells were washed, counted, and resuspended in
DMEM/5% fetal bovine serum.
Flow cytometric analysis. Single-cell suspensions were preincubated in
2.4G2 hybridoma supernatant to block Fc
R binding for 15 min and then
incubated with the following conjugated antibodies for 25 min on ice
(B220-FITC, F4/80-PE, CD4-PerCPCy5	5, Gr1-PECy7, CD11b-APC, and CD8-
Paciﬁc Blue). Antibodies used for ﬂow cytometric analysis were purchased
from Becton Dickinson (San Jose, CA) and Ebioscience (San Diego, CA). Cells
were washed, ﬁxed in 4% paraformaldehyde for 8 min, washed again, and then
resuspended in ﬂuorescence-activated cell sorting buffer (1 PBS/1.5% FCS/
0.05% NaN3). Samples were analyzed on a Becton Dickinson LSRII ﬂow
cytometer. At least 20,000 events were collected for each sample, and data
were analyzed using FlowJo software (Treestar, CA).
Statistical analysis. Data are expressed as means  SE. The signiﬁcance of
the difference in mean values was evaluated using a two-way ANOVA with
Duncan’s multiple-range test for post hoc analysis (STATISTICA; StatSoft) and
the Student’s t test, where applicable. The statistical signiﬁcance was at the
P  0.05 level.
RESULTS
Muscle IL-10 levels were measured using enzyme-linked
immunosorbent assay in C57BL/6 mice fed standard diet
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the previous observations in humans (14,15), obese ani-
mals showed signiﬁcantly lower IL-10 levels in muscle
than lean animals (Fig. 1A).
IL-10 treatment prevents diet-induced insulin resis-
tance. We have recently shown that cotreatment with
IL-10 prevents muscle insulin resistance following an
acute lipid infusion (21). In the current study, we deter-
mined the effects of a 3-day IL-10 treatment on diet-
induced insulin resistance. IL-10 treatment increased
circulating IL-10 levels by almost twofold (Fig. 1B). Local
IL-10 levels in gastrocnemius and quadriceps muscle were
increased by 40% (Fig. 1C). IL-10 treatment caused a
modest increase in IL-10 levels in heart, liver, and white
adipose tissue that did not reach statistical signiﬁcance
(Fig. 1D). This may be because basal IL-10 levels are
generally higher in these organs compared with muscle. A
3-week HFD increased whole-body fat mass by approxi-
mately twofold in male C57BL/6 mice, and a 3-day IL-10
treatment did not affect a diet-induced increase in adipos-
ity (Fig. 1E).
A short-term HFD caused insulin resistance in untreated
mice, as indicated by a signiﬁcant reduction in the glucose
infusion rate during hyperinsulinemic-euglycemic clamps
(Fig. 1F). Insulin-stimulated glucose uptake in skeletal
muscle was reduced following HFD (Fig. 1G). Despite
gaining similar adiposity following HFD, IL-10–treated
mice remained insulin sensitive, as indicated by compara-
ble rates of glucose infusion during insulin clamps (Fig.
1F) and by muscle glucose uptake similar to those of
standard diet–fed mice (Fig. 1G). We have previously
shown that lipid-mediated insulin resistance involves de-
fects in muscle insulin signaling (29,30). Following 3
weeks of HFD, insulin-stimulated threonine phosphoryla-
tion of Akt in muscle was signiﬁcantly reduced in control
mice (Fig. 1H). The protective effects of IL-10 against
diet-induced insulin resistance were associated with sig-
niﬁcant increases in muscle Akt phosphorylation and
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FIG. 1. IL-10 treatment protects against diet-induced insulin resistance in C57BL/6 mice. Mice were fed standard diet or HFD for 3 weeks, and
IL-10 or saline (control) was treated for the last 3 days of diet period. A: Muscle IL-10 protein levels in standard diet– and HFD-fed C57BL/6 mice
and in obese RCS10 mice. B: Plasma IL-10 levels following 3 days of chronic IL-10 delivery using osmotic pumps. C: IL-10 protein expression in
gastrocnemius (GAS) and quadriceps (QD) muscle in IL-10–treated and control mice. , Control; f, IL-10 treated. D: Local IL-10 protein levels
in heart, liver, and white adipose tissue (WAT) in IL-10–treated and control mice. , Control; f, IL-10 treated. E: Whole-body fat mass, measured
using
1H-MRS, in standard diet– and HFD-fed mice following IL-10 or saline treatment. , Control; f, IL-10 treated. F: Glucose infusion rates
during hyperinsulinemic-euglycemic clamps. G: Insulin-stimulated glucose uptake in skeletal muscle. H: Insulin-stimulated threonine phosphor-
ylation of Akt and Akt protein levels in muscle. Muscle samples were obtained 15 min after insulin injection. I: Hepatic insulin action expressed
as insulin-mediated percent suppression of basal hepatic glucose production (HGP). Values are means  SE for ﬁve to eight mice in each
experiment. *P < 0.05 vs. standard diet–fed mice or control mice without IL-10 treatment (A–D); *P < 0.05 vs. respective standard diet–fed mice
(E–I). A Student’s t test was used in A–D, and a two-way ANOVA was used in E–I for statistical analysis.
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(Fig. 1H and supplemental Fig. S1A). Muscle IRS-1 activity
was not affected by IL-10 treatment in standard diet–fed
mice. Total IRS-1 and Akt protein levels were also not
affected by the IL-10 treatment. Control mice developed
hepatic insulin resistance after HFD, as reﬂected by a
signiﬁcant reduction in insulin-mediated percent suppres-
sion of hepatic glucose production (HGP) (Fig. 1I). Al-
though there was a trend of improved hepatic insulin
sensitivity in IL-10–treated HFD mice, this difference did
not reach a statistical signiﬁcance. Insulin-stimulated glu-
cose uptake in white adipose tissue tended to be lower
following HFD, and IL-10 treatment did not signiﬁcantly
affect adipose tissue glucose uptake (supplementary Fig.
S1B). These results demonstrate that a 3-day IL-10 treat-
ment ameliorates diet-induced insulin resistance by atten-
uating lipid-mediated defects in muscle insulin signaling
and action without affecting diet-induced obesity. Impor-
tantly, our ﬁndings are consistent with previously ob-
served effects of acute IL-10 treatment in lipid-infused
mice (21).
Generation of transgenic mice with muscle-speciﬁc
overexpression of IL-10. Insulin resistance develops in
multiple organs, and IL-10 receptors are expressed in
many different cell types (31,32). We measured IL-10 R1
protein expression in C2C12 myoblast and myotube cells
and found that IL-10 receptors are expressed in skeletal
muscle (Fig. 2A). To investigate the role of IL-10 in muscle
insulin action, we generated transgenic mice with muscle-
speciﬁc overexpression of murine IL-10 (MCK-IL10),
driven by a modiﬁed mouse MCK gene promoter
(1256MCK-3Emut) that is preferentially active in skeletal
muscle (24,25) (Fig. 2B). The potential advantage of using
the 1256MCK-3Emut promoter for IL-10 expression is
that locally secreted IL-10 might have beneﬁcial effects in
skeletal muscle tissue that would only be achieved by
much higher systemic levels of IL-10, thereby avoiding
potential negative consequences of high systemic IL-10
concentrations. We identiﬁed founder lines with high and
low expression of IL-10, and these mice were back-crossed
to C57BL/6 mice. Initial characterization showed compa-
rable metabolic proﬁle (e.g., glucose, insulin levels) in
both high and low expressors (data not shown). The
studies reported below concern a single transgenic line of
MCK-IL10 mice (low expressors) in which the relative
increase in skeletal muscle IL-10 levels above endogenous
levels was twice as high as the relative increase in plasma
IL-10 levels above endogenous levels.
MCK-IL10 mice showed no notable sign of anomaly (Fig.
2C), and their organ weights (e.g., skeletal muscle, adipose
tissue, liver, heart) were comparable with those of non-
transgenics (wild type; C57BL/6) (data not shown). MCK-
IL10 mice developed normally and displayed a similar
pattern of growth compared with wild-type littermates
FIG. 2. Transgenic mice with muscle-speciﬁc overexpression of IL-10 (MCK-IL10). A: IL-10R1 protein expression in C2C12 myoblast and myotube
cells. B: Map of MCK-IL10 construct. C: Photographs of MCK-IL10 mice and WT littermates. D: Body weight. E: Whole body lean and fat mass. F:
Hematoxylin-eosin staining of gastrocnemius (GAS) and quadriceps (QD) muscle. G: Muscle IL-10 protein levels. H: Plasma and local IL-10
protein levels in heart, liver, and white adipose tissue (WAT). I: STAT3 activity (Tyr
705phosphorylation of STAT3) in skeletal muscle. Values are
means  SE for six to eight mice in each group. *P < 0.05 vs. WT mice. A Student’s t test was used for statistical analysis. (A high-quality color
digital representation of this ﬁgure is available in the online issue.)
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morphology and architecture of skeletal muscle, as indi-
cated in hematoxylin-eosin staining of muscle samples
(Fig. 2F). The tissue-speciﬁc nature of transgene expres-
sion at the protein level was determined using enzyme-
linked immunosorbent assays in MCK-IL10 and wild-type
mice. Local IL-10 protein levels were elevated by approx-
imately twofold in skeletal muscle of MCK-IL10 mice
compared with wild-type littermates (Fig. 2G). Plasma
IL-10 levels were modestly elevated by 30% in MCK-IL10
mice (13.3  1.2 vs. 9.7  0.3 pg/ml in wild-type mice; P 
0.05), suggesting that transgene-driven IL-10 was released
from skeletal muscle ﬁbers following its synthesis. IL-10
protein expression was not signiﬁcantly altered in white
adipose tissue, liver, and heart of MCK-IL10 mice (Fig.
2H). To determine whether the increased muscle IL-10
levels in MCK-IL10 mice affect known intracellular IL-10
targets, we performed Western blot analysis to measure
tyrosine phosphorylation of STAT3, a major intracellular
IL-10 signaling protein (18). Our results indicate that Tyr
705
phosphorylation of STAT3 was increased by more than
threefold in skeletal muscle of MCK-IL10 mice (Fig. 2I),
while total STAT3 protein levels remained unaltered. In
contrast, phospho-tyrosine STAT3-to-STAT3 ratio in liver
samples was comparable between wild-type and MCK-IL10
mice (0.47  0.14 in wild-type liver vs. 0.33  0.03 in
MCK-IL10 liver; P  0.1). Thus, these results indicate that
MCK-IL10 mice have a physiological and selective increase
in IL-10 protein expression in muscle without altered
expression in other insulin-sensitive organs (e.g., liver,
adipose tissue). Additionally, MCK-IL10 mice showed
markedly enhanced IL-10 signaling in muscle as reﬂected
by increased STAT3 activity.
MCK-IL10 mice are protected against diet-induced
insulin resistance in skeletal muscle. A 3-day analysis
of energy balance in MCK-IL10 mice and wild-type litter-
mates fed a standard diet was performed using metabolic
cages. Daily food intake, VO2 consumption (energy expen-
diture), and physical activity were not signiﬁcantly altered
in MCK-IL10 mice (Fig. 3A–C and supplementary Fig.
S2A). This is consistent with normal body size and adipos-
ity in MCK-IL10 mice. To determine the effects of diet-
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mice and wild-type littermates were fed an HFD or stan-
dard diet for 3 weeks. Food intake, VO2 consumption, and
physical activity remained comparable in MCK-IL10 and
wild-type mice following HFD (Fig. 3A–C and supplemen-
tary Fig. S2B). Muscle overexpression of IL-10 did not
affect body composition, and MCK-IL10 mice gained a
comparable increase in whole-body fat mass following
HFD (Fig. 3D). Despite a similar degree of adiposity, basal
plasma glucose levels were lower in MCK-IL10 mice fed a
standard or HFD (Fig. 3E). A 3-week HFD markedly raised
basal insulin levels in wild-type mice, reﬂecting a second-
ary islet response to systemic insulin resistance (Fig. 3F).
Although HFD increased basal insulin levels in MCK-IL10
mice, such levels were signiﬁcantly lower as compared
with the HFD-fed wild-type mice, suggesting enhanced
insulin sensitivity in MCK-IL10 mice.
A 2-h hyperinsulinemic-euglycemic clamp was per-
formed in conscious male MCK-IL10 mice and wild-type
littermates to assess whole-body insulin sensitivity. MCK-
IL10 mice fed a standard diet were more insulin sensitive
than wild-type mice, as indicated by signiﬁcant increases
in steady-state glucose infusion rates and whole-body
glucose turnover during clamps (Fig. 3G and H). These
results demonstrate that IL-10 expression in muscle in-
creases whole-body insulin sensitivity in transgenic ani-
mals, implicating IL-10 as a positive regulator of insulin
sensitivity. Following HFD, MCK-IL10 mice remained
more insulin sensitive and showed an 40% increase in
insulin-stimulated whole-body glucose turnover (Fig. 3H)
and more than a twofold increase in whole-body glycogen
plus lipid synthesis compared with the HFD-fed wild-type
mice (data not shown).
IL-10–mediated protection against diet-induced insulin
resistance was mostly due to an 50% increases in insulin-
stimulated glucose uptake in skeletal muscle of MCK-IL10
mice (Fig. 3I). This was associated with approximately
twofold increases in insulin-stimulated tyrosine phosphor-
ylation of IRS-1, a major intracellular insulin-signaling
event leading to glucose metabolism (33) in MCK-IL10
mice fed standard diet or HFD (Fig. 4A). Protein kinase
C-
, a serine kinase that negatively regulates muscle
insulin signaling (34,35), was reduced in MCK-IL10 mice
compared with wild-type mice following HFD (data not
shown). HFD reduced hepatic insulin action in both wild-
type and MCK-IL10 mice (Fig. 4B), indicating that diet-
induced hepatic insulin resistance was not affected by
muscle overexpression of IL-10.
High-fat diet increases macrophages and cytokines in
skeletal muscle. Recent reports (9,23,36) indicate that
obesity-associated insulin resistance is partly due to
chronic low-grade inﬂammation and increased macro-
phage inﬁltration in adipose tissue. Since skeletal muscle
is a major insulin-sensitive organ, we examined the effects
of HFD on the inﬂammatory response in muscle. Remark-
ably, skeletal muscle levels of CD68 (a macrophage-
speciﬁc marker) were increased by 70% in wild-type
mice following 3 weeks of HFD (Fig. 5A). To our
knowledge, this is the ﬁrst report of elevated macro-
phage levels in skeletal muscle in normal mice
(C57BL/6) following a short-term HFD. Importantly,
muscle CD68 protein expression was completely nor-
malized in HFD-fed MCK-IL10 mice (Fig. 5A). In contrast
to skeletal muscle, CD68 protein levels in adipose tissue
were similarly elevated in HFD-fed wild-type and MCK-
IL10 mice (data not shown).
We performed immunohistochemistry and immunoﬂuo-
rescence studies using anti-CD68 and F4/80 and found
increased expression of macrophage markers in wild-type
muscle following HFD (Fig. 5B and C and Fig. 6). Consis-
tent with the CD68 protein expression data, muscle IL-10
expression attenuated a diet-induced increase in F4/80
levels in skeletal muscle (Fig. 5C and Fig. 6). To further
examine diet-induced macrophage inﬁltration and IL-10–
mediated attenuation of inﬂammatory response in skeletal
muscle, we performed ﬂow cytometric analysis using
conjugated antibodies against F4/80 and CD11b. An in-
creased number of mononuclear cells including macro-
phages were recovered from wild-type skeletal muscle
following HFD, and this inﬂammatory response was atten-
uated in IL-10–overexpressing mice (Fig. 5D and E).
To determine the underlying mechanism of increased
macrophages in skeletal muscle following HFD, we mea-
sured muscle protein expression of CCR2, which binds the
monocyte chemoattractant protein (MCP)-1 and regulates
macrophage recruitment (37,38). HFD caused a twofold
increase in muscle CCR2 levels in wild-type mice, but
muscle IL-10 expression completely prevented a diet-
induced increase in muscle CCR2 levels (Fig. 7A). Given
our recent study (39) showing activation of the stress
kinase, JNK, in inﬂammation-associated insulin resistance,
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cate that HFD caused an 45% increase in phospho-JNK1–
to–JNK1 ratio in wild-type mice (P  0.03), and this ratio
was markedly lower in MCK-IL10 mice on standard diet
and HFD compared with wild-type mice on a respective
diet (Fig. 7B).
Since inﬂammatory cytokines play a major role in
insulin resistance, we measured serum and local cytokine
levels in wild-type and MCK-IL10 mice fed a standard diet
or HFD. None of the cytokine levels were altered in
MCK-IL10 mice fed a standard diet. In contrast, HFD
signiﬁcantly elevated muscle and plasma levels of IL-6 and
TNF- (Fig. 8A–D). Diet-induced increases in inﬂamma-
tory cytokines were completely attenuated in MCK-IL10
mice. Local IL-10 protein levels were selectively in-
creased in skeletal muscle of MCK-IL10 mice (Fig. 8E).
IL-10 levels in liver and white adipose tissue tended to
be lower in wild-type mice following HFD, and these
levels were not altered in MCK-IL10 mice (Fig. 8F and
G). Intramuscular triglyceride levels were not altered
following a 3-day IL-10 treatment and were similarly
elevated in wild-type and MCK-IL10 mice following HFD
(Fig. 8H and I). These results demonstrate that diet-
induced macrophage inﬁltration in skeletal muscle
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the associated inﬂammatory response is attenuated in
MCK-IL10 mice.
DISCUSSION
In this article, we show that transgenic mice with muscle-
speciﬁc overexpression of IL-10 were protected from
diet-induced insulin resistance in skeletal muscle, and this
was associated with increased IRS-1 and Akt activities and
reduced levels of macrophages and cytokines in skeletal
muscle. These results are consistent with our observations
that IL-10 treatment in normal mice prevents lipid-medi-
ated insulin resistance in skeletal muscle. Taken together,
our ﬁndings indicate that IL-10 is a positive regulator of
muscle insulin sensitivity and that IL-10 prevents muscle
insulin resistance by attenuating an obesity-associated
macrophage and cytokine response in muscle.
Increasing evidence indicates the role of chronic low-
grade inﬂammation and macrophage activation in insulin
resistance (9,23,36). A cohort of recent studies have dem-
onstrated increases in macrophage inﬁltration and cyto-
kine expression in adipose tissue and their association
with insulin resistance in obese humans and animal mod-
els (40–42). Obesity-induced macrophage inﬁltration is
associated with increased adipocyte expression of MCP-1
and macrophage inﬂammatory protein-1 (37,43–45). Ad-
ditionally, mice with adipocyte-speciﬁc overexpression of
MCP-1 (ap2-MCP-1) develop insulin resistance associated
with increased macrophage inﬁltration in adipose tissue
(44). CCR2 binds to MCP-1 and regulates macrophage
recruitment, and CCR2 knockout mice show increased
insulin sensitivity with reduced macrophage level in adi-
pose tissue (38). Although these ﬁndings support the role
of adipose inﬁltration of macrophages in insulin resis-
tance, it remains unclear whether macrophage inﬁltration
is a cause or consequence of insulin resistance. In this
regard, macrophage inﬁltration in obese mice (e.g., leptin-
deﬁcient ob/ob mice) may be triggered by adipocyte hyper-
Wild-type
Wild-type
High-Fat Diet
Nuclear - DAPI F4/80 - FITC DAPI - FITC 
MCK-IL10
MCK-IL10
High-Fat Diet
FIG. 6. Immunoﬂuorescence analysis using anti-F4/80 (green labeling) and nuclei labeling with DAPI (blue labeling) in skeletal muscle in WT and
MCK-IL10 mice following standard diet or HFD for 3 weeks. (A high-quality color digital representation of this ﬁgure is available in the online
issue.)
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(46). It is also unclear whether macrophages inﬁltrate into
skeletal muscle in obesity and whether this directly con-
tributes to muscle insulin resistance, an important primary
event in the development of type 2 diabetes.
Here, we report for the ﬁrst time that a short-term (3
weeks) feeding of HFD increased macrophage inﬁltration
in skeletal muscle that was associated with increased
muscle expression of CCR2. We also found that macro-
phage levels in adipose tissue were elevated after 3 weeks
of HFD in wild-type mice. Since 3 weeks of HFD is
the earliest inducible time point of diet-induced insulin
resistance (29), these results support the notion that
macrophage inﬁltration is causally associated with obesity-
associated insulin resistance in skeletal muscle. Diet-
induced macrophage inﬁltration in muscle was associated
with increased muscle expression of TNF- and IL-6.
TNF- is a proinﬂammatory cytokine that is actively
secreted by macrophages and adipocytes and shown to
cause insulin resistance by downregulating AMP-activated
protein kinase (12,47). Furthermore, IL-6 is a proinﬂam-
matory cytokine that is elevated in obese, diabetic sub-
jects and shown to cause insulin resistance by activating
STAT3-SOCS3 expression and inhibiting the insulin signal-
ing pathway in liver (11,48,49). Thus, our ﬁndings indicate
that diet-induced insulin resistance is in part due to
increases in macrophage inﬁltration and local levels of
TNF- and IL-6 in skeletal muscle and subsequent delete-
rious effects of these cytokines on the muscle insulin
signaling. Although recent studies have argued the role of
IL-6 in insulin resistance, more studies are clearly needed
to determine the metabolic role of IL-6 in diabetic skeletal
muscle (50,51). We should also point out that these results
do not argue against the role of adipose tissue macro-
phages and inﬂammation in obesity-induced insulin
resistance. Instead, our report implicates that local inﬂam-
mation in skeletal muscle may be an additional mechanism
by which modest obesity affects muscle insulin action.
The protective effects of IL-10 against diet-induced
defects in muscle insulin signaling and glucose metabo-
lism were associated with reductions in macrophage levels
and local cytokine expressions in skeletal muscle of
HFD-fed MCK-IL10 mice. Muscle IL-10 expression also
blunted diet-induced increases in CCR2 protein expression
in muscle. These results demonstrate that the anti-inﬂam-
matory action of IL-10 prevents the obesity-induced CCR2
expression and macrophage inﬁltration in skeletal muscle,
which attenuates the deleterious effects of local cytokines
on muscle insulin signaling and glucose metabolism.
Taken together, our ﬁndings indicate a causative role of
macrophage inﬁltration and local cytokines on obesity-
associated insulin resistance, and they support a role of
IL-10 in the regulation of glucose homeostasis. However,
our ﬁndings do not rule out the role of local lipids or lipid
metabolites in muscle insulin resistance following chronic
high-fat feeding.
The ability of IL-10 secreted in skeletal muscle to
attenuate several of the pathogenic insulin-signaling phe-
notypes associated with type 2 diabetes is interesting with
respect to the design of future therapeutic treatments for
this disease. While potential problems associated with
chronically elevated levels of IL-10 would require further
investigation, the relatively low levels of IL-10 (30% in
plasma and 100% in skeletal muscle) tested in the present
study did not appear deleterious to the mice. Numerous
alternative versions of MCK-based regulatory gene cas-
settes have been designed and tested in mice in conjunc-
tion with both systemic and intramuscular delivery with
adeno-associated virus vectors (52,53). Since these cas-
settes are striated muscle-speciﬁc and have a range of
transcriptional activities, it should, in principle, be feasible
to design optimal combinations of MCK-IL10 gene expres-
sion constructs, adeno-associated virus titers, and vector
delivery routes that would lead to the secretion of sufﬁ-
cient intramuscular or systemic levels of IL-10 to possibly
improve insulin sensitivity in type 2 diabetes.
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